Leg cramps are not listed as a recognised adverse effect in the UK Summaries of Product Characteristics (SmPCs) for GLP-1 receptor agonists, and evidence for a causal link is limited
In the 2025 FDA label, the SURPASS-1 monotherapy trial showed statistically significant A1c reductions versus placebo over 40 weeks, with body-weight reductions ranging from 6.3 kg to 7.8 kg depending on dose
Common adverse effects include gastrointestinal symptoms such as nausea, vomiting, diarrhoea, and constipation, which are typically more common during treatment initiation and after dose increases, and often improve with time and gradual titration
ACE2 enzyme degrades ANG II, the major effector of the RAAS that increases hypertension (by lowering baroreceptor sensitivity) to control heart rate, up-regulate vasoconstriction, sodium retention, OxS, inflammation, and fibrosis 300
TB-500's extends to cardiac and skeletal muscle, giving the combination broader coverage than either compound alone
Captivating colors, crucial roles: Astaxanthins antioxidant impact on fish oxidative stress and reproductive performance
